Leap Therapeutics, Inc. (LPTX) stock declined over -9.15%, trading at $0.52 on NASDAQ, down from the previous close of $0.57. The stock opened at $0.55, fluctuating between $0.51 and $0.57 in the recent session.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Employees | 54 |
Beta | 0.22 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Leap Therapeutics, Inc. (NASDAQ: LPTX) stock price is $0.52 in the last trading session. During the trading session, LPTX stock reached the peak price of $0.57 while $0.51 was the lowest point it dropped to. The percentage change in LPTX stock occurred in the recent session was -9.15% while the dollar amount for the price change in LPTX stock was -$0.05.
The NASDAQ listed LPTX is part of Biotechnology industry that operates in the broader Healthcare sector. Leap Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Jason S. Baum Ph.D.
Chief Scientific Officer
Mr. Douglas E. Onsi J.D.
Chief Financial Officer, Gen. Counsel, Treasurer & Sec., Pres, Chief Executive Officer & Director
Dr. Cynthia A. Sirard
Chief Medical Officer
Mr. Mark O'Mahony
Chief Manufacturing Officer
Mr. Augustine J. Lawlor
Chief Operating Officer
Dr. Walter Newman
Senior Research Fellow
Ms. Christine M. Granfield
Vice President and Head of Regulatory Affairs & Quality
LPTX's closing price is 1.74% higher than its 52-week low of $0.51 where as its distance from 52-week high of $4.79 is -89.16%.
Number of LPTX employees currently stands at 54.
Official Website of LPTX is: https://www.leaptx.com
LPTX could be contacted at phone 617 714 0360 and can also be accessed through its website. LPTX operates from 47 Thorndike Street, Cambridge, MA 02141, United States.
LPTX stock volume for the day was 1.95M shares. The average number of LPTX shares traded daily for last 3 months was 661.79K.
The market value of LPTX currently stands at $19.90M with its latest stock price at $0.52 and 38.32M of its shares outstanding.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com